![Krisztina Nemenyi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Krisztina Nemenyi
Consigliere Generale presso CYTEIR THERAPEUTICS, INC.
Profilo
Krisztina Nemenyi is currently the Head-Asia Pacific Global Regulatory Affairs at Bristol Myers Squibb Co. She is also currently serving as the Senior Vice President-Regulatory Affairs & Quality at Cyteir Therapeutics, Inc. In the past, she worked as the VP-Emerging Markets Global Regulatory Affairs at Takeda Pharmaceuticals U.S.A., Inc. Dr. Nemenyi holds a doctorate degree from the University of Vienna and a graduate degree from Budapest University of Technology & Economics.
Posizioni attive di Krisztina Nemenyi
Società | Posizione | Inizio |
---|---|---|
CYTEIR THERAPEUTICS, INC. | Consigliere Generale | 03/05/2022 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Precedenti posizioni note di Krisztina Nemenyi
Società | Posizione | Fine |
---|---|---|
Takeda Pharmaceuticals U.S.A., Inc.
![]() Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | - |
Formazione di Krisztina Nemenyi
University of Vienna | Doctorate Degree |
Budapest University of Technology & Economics | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Aziende private | 2 |
---|---|
Cyteir Therapeutics, Inc.
![]() Cyteir Therapeutics, Inc. BiotechnologyHealth Technology Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company was founded by Kevin Mills and Timothy Romberger in June 2012 and is headquartered in Lexington, MA. | Health Technology |
Takeda Pharmaceuticals U.S.A., Inc.
![]() Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |
- Borsa valori
- Insiders
- Krisztina Nemenyi